A personalized mRNA cancer vaccine sponsored by Moderna and Merck has the potential to change the standard of care for melanoma patients—and reshape the landscape of cancer vaccines—if the company’s latest data on the vaccine are validated in a phase III clinical trial.
Immune-checkpoint therapy, which attempts to harness a patient’s own immune system to fight cancer, has revolutionized cancer care over the past two decades.
